Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

14.36 +0.06 (+0.42%)
Streaming Delayed Price Updated: 11:57 AM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
From MediWound Ltd.
Via GlobeNewswire
News headline image
Preview: MediWound's Earnings ↗
 
Via Benzinga
News headline image
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
Cowen & Co. Maintains Outperform Rating for MediWound: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
FDA Approves MediWound's NexoBrid For Burn Treatment ↗
 
Via Benzinga
News headline image
Recap: MediWound Q2 Earnings ↗
  MediWound (NASDAQ:MDWD) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
MediWound Posts Early Data From Non-Melanoma Skin Cancer Trial ↗
 
Via Benzinga
News headline image
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
From MediWound Ltd.
Via GlobeNewswire
News headline image
Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
UBS cut Microsoft Corporation (NASDAQ: MSFT) price target from $300 to $250. UBS analyst Karl Keirstead downgraded the stock from Buy to Neutral. Microsoft shares fell 2% to $234.73 in pre-market... 
Via Benzinga
News headline image
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
News headline image
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
News headline image
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Strengthens European Presence of NexoBrid®
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical company 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces a 1-for-7 Reverse Share Split
From MediWound Ltd.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 15, 2022 ↗
Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million. 
Via Benzinga
News headline image
MediWound to Report Third Quarter 2022 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Formation of Strategic Advisory Board
Esteemed group of industry leaders to contribute expertise and experience to MediWound’s strategic and operational activities 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
EscharEx’s promising results from the completed Phase 2 trials were highlighted 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
Gross Proceeds of $30.5 Million Raised 
From MediWound Ltd.
Via GlobeNewswire
News headline image
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Dow Turns Higher; Crude Oil Rises 0.7% ↗
U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday. 
Via Benzinga
News headline image
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session ↗
 Gainers 
Via Benzinga
News headline image
Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher ↗
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday. 
Via Benzinga
News headline image
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
FDA Accepts MediWound's Refiling For Severe Thermal Burns Therapy For Review ↗
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ: MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.